By Teis Jensen COPENHAGEN (Reuters) - Positive results from a trial by Danish biotech company Genmab of its bone marrow cancer drug could lead to a launch as early as this year and it may become a blockbuster treatment earning $3.5 billion in annual revenues, analysts said. Genmab said the study of daratumumab, which evaluated multiple myeloma patients who had already had at least three different lines of therapy unsuccessfully, showed an overall response rate of 29.2 percent. The response rate indicated Genmab's drug worked better than two recently approved drugs, Onyx Pharmaceuticals' Kyprolis and Celgene's Pomalyst, although these have been tested in different ways, Sydbank analyst Soren Lontoft Hansen said. Shares in Genmab rose by as much as 10 percent early on Wednesday to a record high of 467.80 Danish crowns per share before trimming gains to 461 crowns at 1129 GMT. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment